<DOC>
	<DOCNO>NCT01224457</DOCNO>
	<brief_summary>The pharmacogenomic profile drug metabolizing enzyme play important role pharmacokinetics ( PK ) drug . Phenobarbital ( PB ) , worldwidely use neonatal seizure , drug require careful dose adjustment base therapeutic drug monitoring . It report phenobarbital ( PB ) metabolism affect CYP2C9 CYP2C19 polymorphism adult . This study aim evaluate effect CYP2C9 CYP2C19 genetic polymorphism PB PK infant neonatal seizure optimal dosing strategy .</brief_summary>
	<brief_title>Effect CYP2C9/CYP2C19 Polymorphism Pharmacokinetics Phenobarbital Korean Neonatal Seizure Patients .</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>Infant treat phenobarbital monotherapy , diagnose neonatal seizure Infant take drug concentration one time give informed consent progress CNS disorder severe systemic illness GOT/GPT level 2times normal value , 3times elevation BUN/creatinine level congenital hemolytic anemia genetic disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>